Trovagene, a cell-free molecular diagnostics company in San Diego, California, has terminated the employment of CEO Antonius Schuh and CFO Stephen Zaniboni for withholding new therapeutics in the field of precision medicine for their own benefit. The firm filed a complaint against Schuh and Zaniboni for breach of fiduciary duty, which was filed in the Superior Court of the State of California for the County of San Diego. The complaint requests Schuh and Zaniboni to turn over their interests in these new therapeutics to Trovagene.
Oxford Pharmascience, a London-based company which redevelops medicines, has appointed Anand Sharma as a non-executive director.
Adaptive Biotechnologies, a sequencing and bioinformatics company based in Seattle, Washington, has appointed Diego Miralles as president of Adaptive Therapeutics. Miralles will build the Therapeutics Division of Adaptive, and head the company’s efforts to leverage its platform for identifying T- and B-cell receptors for use in therapies. He will provide both scientific and commercial guidance to the existing and future programs and partnerships that Adaptive is implementing
Mirati Therapeutics, a targeted oncology company based in San Diego, California, has promoted Vice President of Finance Jamie A. Donadio to Senior Vice President and Chief Financial Officer. In his new role, Donadio will be responsible for all corporate finance and accounting activities for the company.
Rigel Pharmaceuticals, a clinical-stage biotechnology company focused on immunology, oncology and immuno-oncology, has appointed Anne-Marie Duliege as chief medical officer to replace Elliott Grossbard, who is to retire after 14 years of service. Grossbard will remain with the company, advising on the new drug application (NDA) filing and regulatory strategy for fostamatinib in immune thrombocytopenic purpura (ITP).
Sorrento Therapeutics, clinical-stage biopharmaceutical company in San Diego, and Yuhan Corporation, an established health care company based in Seoul, have entered into an agreement to form a joint venture, ImmuneOncia Therapeutics. The joint venture will develop and commercialise a number of immune checkpoint antibodies against undisclosed targets for both hematological malignancies and solid tumors.